CD19-specific CAR T-cells have been used successfully to treat acute lymphoblastic leukemia (ALL) by eliminating both malignant and normal B-cells, since CD19 is also expressed on normal cells. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.